WSI Policy Statement Approval of ‘Dispense as Written’ Prescriptions
(Effective August 2011)

WSI will provide coverage for the brand name medication in lieu of the generic equivalent in the following instances:

- Cases in which there is documentation of an adverse reaction with the generic medication that was not present with the equivalent brand name product. Such reactions must be documented in the medical notes with a specific reference to the reaction having only occurred with the generic medication and not the equivalent brand name product.

- Cases in which there is documentation of an inadequate therapeutic response with the generic medication that was not present with the equivalent brand name product. The inadequate therapeutic response must be documented in the medical notes and must contain measurable, objective medical evidence. Statements that imply that the equivalent brand name product exerted a superior therapeutic response when compared to the generic equivalent product without documentation of measurable, objective medical evidence may result in denial of the brand name product.

Complete the [Provider’s Request for Medical Prior Authorization (M11) form](#). Fax this form, along with the supporting documentation as stated above to WSI to 888-786-8695.

If you have any questions, please contact WSI at 800.777.5033 or 701.328.3800